The Triage PₗGF test helps in evaluating the risk of maternal and fetal complications. Credit: QuidelOrtho Corporation.

Diagnostic healthcare solutions provider QuidelOrtho has announced that its Triage placental growth factor (PₗGF) test has received Health Canada approval for in-lab use.

The Triage PₗGF test is a fluorescence immunoassay and is intended to be used with the small-footprint Triage MeterPro Instrument.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It is used for the quantitative determination of PₗGF in maternal plasma specimens.

The test can detect the presence of angiogenic imbalance, due to abnormal placentation and poor blood flow in the placenta that can lead to maternal and fetal complications of pregnancy, including pre-eclampsia.

Together with other clinical information, the Triage PₗGF test aids in diagnosing preterm pre-eclampsia. It can also help in assessing the risk of imminent delivery in symptomatic women between 20 and 35 weeks of gestation.

See Also:

QuidelOrtho Canada country director Bernard Michaud said: “When signs or symptoms of pre-eclampsia are present, it is critical to the health and safety of the mother and her unborn baby that clinicians have the information necessary to determine the optimal course of action to achieve the best possible outcome for the pregnancy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The Triage PₗGF test is intended to help clinicians diagnose pre-eclampsia sooner and may provide them with information on whether the pregnancy is likely to deteriorate within the next 14 days, allowing for a better patient care management plan.”

The test enables clinicians to better detect angiogenic imbalance and evaluate the risk of maternal and fetal complications.

Capable of providing results within approximately 15 minutes, the test is said to provide high accuracy to support the clinical diagnosis of pre-eclampsia requiring delivery within 14 days.

It is also expected to contribute to a 20% reduction in maternal adverse outcomes when incorporated into clinical guidelines.

Last year, QuidelOrtho obtained De Novo authorisation from the US Food and Drug Administration (FDA) for its Sofia 2 SARS Antigen+ FIA test.